The same enzymes that made gene editing famous have been repurposed into diagnostic tools through a mechanism called collateral cleavage. When a Cas enzyme finds its matching genetic sequence, it switches on and begins cutting any nearby reporter molecules, releasing a fluorescent or colored signal that reveals the pathogen or biomarker's presence. Two platforms built on this principle, SHERLOCK and DETECTR, are being developed to detect targets ranging from SARS-CoV-2 and tuberculosis bacteria to malaria parasites and cancer biomarkers in circulating tumor DNA.

How CRISPR Diagnostics Work: The Collateral Cleavage Mechanism

In its native role, a CRISPR/Cas system is a bacterial immune defense: a guide RNA leads the Cas enzyme to a specific nucleic acid sequence, which the enzyme then cuts. Diagnostics exploit the same recognition machinery, but with a twist. As a review of CRISPR-driven diagnostics in the journal Frontiers in Cellular and Infection Microbiology explains, when target nucleic acids are present in a sample, the Cas protein–crRNA complex binds to the sequence and activates a trans-cleavage function that cuts fluorescently or biotin-labeled reporter molecules, generating a detectable signal.

The crucial insight is that the enzyme's cutting behavior changes once it has found its target. Before recognition, the Cas enzyme is precise and restrained. After binding its complementary target, it becomes indiscriminate, slicing any nearby single-stranded reporter molecules regardless of their sequence. This "collateral cleavage" is what turns a single molecular recognition event into an amplified, readable output.

That amplification is the diagnostic engine. One activated enzyme can cleave many reporter molecules, so a vanishingly small amount of target genetic material can produce a visible signal. According to the Frontiers review, this gives CRISPR-based assays attomolar sensitivity, superior specificity, and operational simplicity compared with conventional PCR and ELISA, making them particularly suitable for point-of-care testing.

The Four Stages of CRISPR Diagnostic Signal Generation

The mechanism can be broken into a sequential four-stage model, which shows how a highly specific binding event becomes a non-specific, measurable signal:

  1. Target recognition. A guide RNA (gRNA) is designed to be complementary to the target nucleic acid sequence of the pathogen or biomarker of interest. The gRNA's sequence dictates the specificity of the target, and the Cas enzyme–gRNA complex searches the sample for its match.
  2. Cas enzyme activation. When the gRNA finds and binds its target, the Cas enzyme undergoes activation of its nuclease activity. This activation is the key step that unlocks subsequent signal generation.
  3. Collateral cleavage. The activated enzyme then indiscriminately cleaves nearby single-stranded reporter molecules—DNA reporters for Cas12, RNA reporters for Cas13—that are not sequence-specific to the target. This trans-cleavage activity amplifies the signal, since each activated enzyme can cut many reporters.
  4. Signal generation. Cleaving the reporters releases a detectable signal, such as fluorescence or a color change, indicating the presence of the target nucleic acid. The type of signal depends on the reporter molecule used.

The elegance of the design lies in this division of labor: specificity comes entirely from the guide RNA's pairing with the target, while the readout comes from the generic destruction of reporters. A review of rapid SARS-CoV-2 detection platforms published through the National Library of Medicine describes this directly for Cas13: specificity is conferred by crRNA–target pairing, and sensitivity is achieved through signal amplification by the collateral cleavage of added RNA reporters, which can be captured on a colorimetric lateral-flow strip or visualized by fluorescence.

Key CRISPR Diagnostic Platforms: DETECTR and SHERLOCK

The two leading platforms apply the same collateral-cleavage principle with different enzymes and different target chemistries. DETECTR (DNA Endonuclease Targeted CRISPR Trans Reporter) is built on Cas12a, a DNA-targeting enzyme. As described in a review of CRISPR/Cas diagnosis of infectious diseases published by LIDSEN Publishing, when target DNA is present, the Cas12a–gRNA complex binds the guide-complementary target DNA, forming a triplex of gRNA and double-stranded DNA. That triplex activates Cas12a's trans-cleavage activity, allowing it to fragment nearby single-stranded DNA non-specifically. DETECTR monitors this activity using ssDNA reporters labeled with a fluorophore–quencher pair: cleavage separates the fluorophore from the quencher, and light escapes.

SHERLOCK (Specific High-sensitivity Enzymatic Reporter unlocking) instead pairs Cas13, an RNA-targeting enzyme, with single-stranded RNA reporters. Because Cas13 naturally targets RNA, SHERLOCK is well matched to RNA viruses and other RNA targets, while DETECTR's Cas12a handles DNA. Both platforms, alongside others such as HOLMESv2, were cited in a PMC review of CRISPR-driven diagnostics as evidence that CRISPR-based assays can serve as effective alternatives to traditional molecular methods.

The performance reported for SHERLOCK illustrates what the mechanism delivers. According to the SARS-CoV-2 detection review, SHERLOCK allows rapid detection—completed in as little as one hour with a setup time under 15 minutes—of nucleic acids at concentrations down to approximately 2 attomolar, with single base-pair mismatch specificity. That single-base resolution means a well-designed assay can distinguish closely related pathogen strains, a capability that conventional immunological tests generally lack.

A comparison of the two platforms makes the design trade-offs clear:

DETECTR versus SHERLOCK: core components and target chemistry
PlatformKey enzymePrimary targetReporter molecules
DETECTRCas12aDNA sequencesssDNA reporters (fluorophore–quencher labeled)
SHERLOCKCas13RNA sequencesssRNA reporters (fluorescent or lateral-flow labeled)

Both platforms use the same underlying logic—guide-directed recognition followed by collateral cleavage—so the choice between them is largely a choice of target chemistry rather than principle.

SHERLOCK: A CRISPR Tool to Detect DiseaseTo visually demonstrate the SHERLOCK platform's mechanism, enhancing the reader's understanding of the Cas13 collateral cleavage process.Watch on YouTube

Diverse Applications of CRISPR Diagnostics

The applications documented in the scientific literature span infectious and non-infectious disease. On the infectious side, SHERLOCK and DETECTR were rapidly adapted for SARS-CoV-2 detection during the COVID-19 pandemic, offering rapid and accurate results with sensitivity and specificity comparable to PCR and potential for point-of-care use, as reported by News-Medical's coverage of the field.

Beyond viruses, CRISPR-based assays have shown promise in diagnosing bacterial infections, including Mycobacterium tuberculosis, the bacterium responsible for tuberculosis. They have also been used successfully to detect different Plasmodium species in patient blood samples, which the reporting describes as a new and powerful tool for malaria diagnosis. The Frontiers review frames the same breadth, noting that clinical validations demonstrate practical utility in detecting drug-resistant bacteria and emerging viruses, and that multiplex platforms can analyze up to 14 targets simultaneously.

Non-infectious applications are also advancing, particularly in oncology. CRISPR-based developments are being used to detect cancer-specific biomarkers in circulating tumor DNA (ctDNA), enabling early detection and monitoring of cancer, with rapid and portable cancer diagnostic tools being developed for use in clinical settings. The PMC review of CRISPR-driven diagnostics adds a cost dimension: it estimates CRISPR-based assays at roughly $2–5 per test, surpassing conventional PCR in workflow simplicity and cost-effectiveness.

It is worth noting the boundaries of this evidence. These figures come from published research and reviews, not from commercial product specifications, and they may not reflect the final price or performance of any marketed test. The platforms discussed here also represent only the Cas12- and Cas13-based systems; other CRISPR/Cas tools, such as Cas9-based NASBACC and Cas14a-based detection of single-stranded DNA, exist but fall outside this article's focus.

Implications for Future Disease Detection

CRISPR-based diagnostics offer a promising avenue for rapid, sensitive, and specific detection of a wide range of pathogens and disease biomarkers, moving toward more accessible and timely diagnostic tools. The mechanism itself—guide-directed recognition converted into collateral-cleavage amplification—explains why these assays can be both highly specific, down to single base pairs, and highly sensitive, down to attomolar concentrations.

For readers tracking whether this promise becomes clinical reality, the measurable indicator is continued research and clinical validation studies demonstrating improved sensitivity, specificity, and ease of use in diverse clinical settings. The documented application areas—SARS-CoV-2, tuberculosis bacteria, malaria parasites, and cancer biomarkers in ctDNA—define the concrete targets against which that progress can be watched.

Sources